Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The dynamic changes of renal function indicators after CAR T-cell infusion.

References

  1. Bradley MA, Gulnaz B, Janet AD, Nicola JB, Faith D, Gareth M, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council Trials Between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26.

    Article  Google Scholar 

  2. Shaji KK, Terry MT, Morie AG, Martha QL, Angela D, S Vincent R, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–74.

    Article  Google Scholar 

  3. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337–41.

    Article  CAS  Google Scholar 

  4. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544–57.

    Article  Google Scholar 

  5. Berdien Oortgiesen, Roshna Azad, Marc Hemmelder, et al. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Haematologica 2018;103:e311–e4.

    Article  Google Scholar 

  6. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953–63.

    Article  CAS  Google Scholar 

  7. Meletios Dimopoulos, David Siegel, Darrell White, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2019;133:147–55.

    Article  Google Scholar 

  8. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728–34.

    Article  CAS  Google Scholar 

  9. Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M, et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016;101:872–8.

    Article  CAS  Google Scholar 

  10. Li AY, Atenafu EG, Bernard RS, Masih-Khan E, Reece D, Franke N, et al. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. Bone Marrow Transplant. 2019;55:578–85

    Article  Google Scholar 

  11. Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, et al. Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transpl. 2018;53:749–55.

    Article  CAS  Google Scholar 

  12. Cornell RF, Kassim A. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: Increased options and increased complexity. Bone Marrow Transplantation. 2016;51:479–91.

    Article  CAS  Google Scholar 

  13. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726–37.

    Article  CAS  Google Scholar 

  14. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;19:3.

  15. Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6:e521–e9.

    Article  Google Scholar 

  16. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

    Article  Google Scholar 

  17. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

    Article  CAS  Google Scholar 

  18. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81930005), National Natural Science Foundation of China Youth Project (No. 81800159).

Author information

Authors and Affiliations

Authors

Contributions

KX, ZL, JZ, and HL were responsible for study design, clinical protocol management, and data interpretation. HL, LY, and YW contributed to data collection and analysis. HL, LY and YW wrote and edited the manuscript. ZL, KX and JZ revised the manuscript. All investigators and their research teams recruited patients and contributed to data collection. All authors reviewed and approved the final manuscript.

Corresponding authors

Correspondence to Junnian Zheng, Zhenyu Li or Kailin Xu.

Ethics declarations

Conflict of interest

GJ is an employee of iCARTAB Biomedical Co Ltd. All other authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Yin, L., Wang, Y. et al. Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment. Bone Marrow Transplant 55, 2215–2218 (2020). https://doi.org/10.1038/s41409-020-0930-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0930-5

Search

Quick links